Lanier Biotherapeutics Announces Issuance of U.S. Patent for IL-25 Binding Molecules
BOGART, Georgia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, Type 2…